Abbvie
Recent News About Abbvie View More
-
AbbVie hit with class action over 'excessive and anticompetitive' Humira pricing
Complaint alleges 470% increase over 2003 price for popular prescription drug -
Fired AbbVie drug reps fail again to advance retaliation lawsuit over federal fraud accusations
Judge determines employees never showed how they accused drug maker of defrauding feds or tried to stop the company from allegedly doing so -
Appeals panel agrees AbbVie didn't violate antitrust laws with Humira 'patent thicket'
Drugmaker settled with potential competitors, but benefit plans fail to prove illegality -
Judge: AbbVie's "patent thicket," deals to keep control over Humira doesn't mean drugmaker broke antitrust laws
AbbVie had accumulated hundreds of patents to protect its claim to Humira's big money sales, but that doesn't mean they broke the law, a judge has ruled, dismissing a slew of class action claims. -
AbbVie to pay $16.8M in fraud suit settlement, attorneys stand to bring in $5M
Plaintiffs’ attorneys stand to make $5 million from the proposed $16.75 million settlement of a class action suit by investors against North Chicago-based drugmaker AbbVie, which alleged the company hid information that led investors to lose money after AbbVie backed out of a merger with a European company. -
AbbVie accused of using 'thicket' of patents to block generic versions of Humira drug from U.S. market
Drug maker AbbVie is facing federal antitrust lawsuits accusing it of using patents to stifle competition and boost the price of its drug, Humira. -
Abbvie wins another bellwether trial amid mass action over Androgel testosterone drug
A federal jury has handed a win to North Chicago-based drugmaker Abbvie, as it continues to seek to fend off a mass of legal claims accusing the company’s testosterone replacement therapy drug, Androgel, of causing heart attacks and other cardiovascular conditions. -
Drug maker AbbVie wants to slip from $140M verdict, says jury ignored evidence
North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA. -
Judge: Testosterone replacement drug bellwether OK to proceed vs Testim maker Auxilium
After two federal juries delivered $140 million verdicts against AbbVie, competing drugmaker Auxilium will be headed to trial over claims its testosterone replacement therapy drug Testim caused heart attacks in men who took the drug to treat “off-label” conditions, spurred by what plaintiffs alleged was misleading marketing from drugmakers. -
Investors allowed to continue pursuing AbbVie in Cook Co court over cancelled Shire acquisition
A group of investor funds will be allowed to continue their fraudulent concealment lawsuit against drugmaker AbbVie in Cook County Circuit Court after a federal judge in Chicago shot down AbbVie’s attempt to relocate to federal jurisdiction the lawsuit over AbbVie's cancelled acquisition of an Irish pharmaceutical company. -
Jury: AbbVie should pay $150M for Androgel marketing; AbbVie: Verdict won't stand
A federal jury has ordered drugmaker AbbVie to pay $150 million in damages for allegedly falsely marketing the benefits of its Androgel testosterone therapy drug, even though the jury did not hold the company liable for a heart attack suffered by a man taking the drug. -
Federal judge tosses some accusations vs testosterone drug makers on eve of Androgel bellwether trials
A Chicago federal judge has dismissed several. but not all of the claims against the maker of a testosterone boosting drug, advanced by several plaintiffs chosen as bellwethers in a class-action lawsuit brought by more than 2,000 plaintiffs from around the U.S. against multiple drug manufacturers, including Besins, AbbVie, Eli Lilly and GlaxoSmithKline. -
Judge tosses insurers' RICO class action vs testosterone drug makers, saying not specific enough
A federal judge has tossed, with leave to amend, the bulk of a federal racketeering and fraud class action brought by an Ohio-based health insurer against Abbvie and other makers of testosterone drugs, saying the insurer has not yet backed up with enough particularity its allegations the drugmakers invented the condition known as “low T,” and, through false marketing to doctors, patients and insurers alike, induced insurers and others to pay far more for the drugs to treat the condition.